ArticleCancer immunology, immunotherapy : CII2019

CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions.

Wanghong Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.